Eventide Asset Management
CLYM icon

Eventide Asset Management’s Climb Bio CLYM Stock Holding History

Eventide Asset Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.37M Buy
+730,000
New +$10.2M 0.12% 161

Other funds holding CLYM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Eventide Asset Management's CLYM Position: Q3 2026 in Review

Eventide Asset Management opened a new position in Climb Bio (CLYM) in Q3 2026: 730,000 shares worth $8.37M. The stake represents 0.12% of the portfolio and ranks #161 among its holdings.

79 funds tracked by Wall St. Rank hold CLYM as of Q3 2026.

  • Eventide Asset Management held 730,000 shares of Climb Bio worth $8.37M as of Q3 2026.
  • Climb Bio was a new Eventide Asset Management position in Q3 2026.
  • Climb Bio made up 0.12% of Eventide Asset Management's portfolio in Q3 2026, its #161 holding.
  • 79 funds tracked by Wall St. Rank held Climb Bio as of Q3 2026.

Based on Eventide Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.